These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 9345399

  • 21. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 22. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS.
    Mult Scler; 1995 Feb; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [Abstract] [Full Text] [Related]

  • 23. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N, Kraus J, Bauer R, Engelhardt B, Bregenzer T, Kuehne BS, Tofighi J, Laske C, Stolz E, Blaes F, Voigt K, Traupe H, Kaps M, Oschmann P.
    Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
    [Abstract] [Full Text] [Related]

  • 24. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 25. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 26. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 27. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J, Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X.
    Ann Neurol; 2002 Oct 20; 52(4):400-6. PubMed ID: 12325067
    [Abstract] [Full Text] [Related]

  • 28. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 29. [The treatment of multiple sclerosis with beta-interferon 1a].
    Rivera VM.
    Rev Neurol; 2009 Nov 10; 31(5):470-1. PubMed ID: 11027100
    [Abstract] [Full Text] [Related]

  • 30. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov 07; 352(9139):1491-7. PubMed ID: 9820296
    [Abstract] [Full Text] [Related]

  • 31. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov 07; 352(9139):1498-504. PubMed ID: 9820297
    [Abstract] [Full Text] [Related]

  • 32. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec 07; 16(92):252-7. PubMed ID: 18092425
    [Abstract] [Full Text] [Related]

  • 33. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
    Motamed MR, Najimi N, Fereshtehnejad SM.
    Clin Neurol Neurosurg; 2007 May 07; 109(4):344-9. PubMed ID: 17300863
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Trials and tribulations: patients' perspectives of the Betaseron study.
    Morrison W.
    Axone; 1994 Dec 07; 16(2):51-5. PubMed ID: 7727297
    [Abstract] [Full Text] [Related]

  • 36. [Treatment of multiple sclerosis using recombinant interferon-beta].
    Polman CH, Barkhof F, van Loenen AC, Lucas CJ, Koetsier JC.
    Ned Tijdschr Geneeskd; 1994 Jan 01; 138(1):7-10. PubMed ID: 8289963
    [No Abstract] [Full Text] [Related]

  • 37. Immunologic therapy of multiple sclerosis.
    Arnason BG.
    Annu Rev Med; 1999 Jan 01; 50():291-302. PubMed ID: 10073279
    [Abstract] [Full Text] [Related]

  • 38. [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland].
    Huber S, Spycher M, Lechner-Scott J, Bellaiche Y, Steck AJ, Kappos L.
    Schweiz Med Wochenschr; 1996 Aug 31; 126(35):1475-81. PubMed ID: 8927950
    [Abstract] [Full Text] [Related]

  • 39. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
    Neurology; 1995 Jul 31; 45(7):1277-85. PubMed ID: 7617182
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
    Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M, SOLAR study group.
    J Neurol Sci; 2011 Dec 15; 311(1-2):44-9. PubMed ID: 21620416
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.